Acute Lymphoblastic Leukemia

347

Pipeline Programs↗

142

Active Trials↗

109

Companies Involved↗

Acute Lymphoblastic Leukemia is a highly competitive landscape with 347 programs across 109 companies. The most active players are Bristol-Myers Squibb, ADC Therapeutics S.A., Syndax Pharmaceuticals. 45 therapies are approved with 60 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

90/100

Pipeline Velocity

46/100

Mech. Concentration

8/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bristol-Myers Squibb

2 programs

ADC Therapeutics S.A.

2 programs

Syndax Pharmaceuticals

2 programs

Chongqing Precision Biotech Co., Ltd

2 programs

Shanghai Simnova Biotechnology Co.,Ltd.

1 program

Sichuan Baili Pharmaceutical Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical26

CTL019

Novartis

Ergocalciferol

Alnylam Pharmaceuticals

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Trivalent Influenza Vaccine

Sinovac Biotech Co., Ltd

Anti-Thymocyte Globulin

Novartis

Phase 187

Idelalisib

Gilead

Pegaspargase

Servier

Influenza Virus Vaccine

Sanofi

Loncastuximab Tesirine

Akero Therapeutics

Ixazomib

Takeda

Phase 2129

Curcumin

Merck & Co.

Decitabine

Sun Pharma

Nilotinib

Azurity Pharmaceuticals

Etoposide Phosphate

German Society for Pediatric Oncology and Hematology GPOH gGmbH

Tafasitamab

Incyte

Phase 360

Asparaginase

Dutch Childhood Oncology Group

Epirubicin Hydrochloride

Merck & Co.

Blinatumomab

Amgen

Dexrazoxane

Pfizer

Tisagenlecleucel

Novartis

Approved45

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Thioguanine

Akero Therapeutics

Mercaptopurine

Stason

Ifosfamide

Baxter Healthcare Corporation

Chlorambucil

Akero Therapeutics

Analysis

Modality Breakdown

71%

Small molecule

263 of 373 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 373 classified programs, each share of the total. Modality classified for 99% of 409 pipeline programs.

Analysis

Trial Status

651

clinical trials

Completed333 · 51%

Recruiting84 · 13%

Terminated82 · 13%

Unknown status61 · 9%

Active, not recruiting46 · 7%

Withdrawn26 · 4%

Other19 · 3%

Clinical Trials

Trial Activity

651 trials

Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia

Recruiting·—·N/A·NCT06756022·500 enrolled

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06427330·21 enrolled

Vitamin A and D Supplementation in Allogeneic HCT

Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06508099·220 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06777979·30 enrolled

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Recruiting·GGuangzhou Women and Children's Medical Center·Phase 1·NCT06752785·10 enrolled

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT06696833·18 enrolled

Shingrix In Recipients of Allogeneic Transplants

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05775718·55 enrolled

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Recruiting·UUniversity of Chicago·Phase 2·NCT04747912·25 enrolled

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03263572·90 enrolled

Effect of Early Administration of Albumin 20% Versus Crystalloid

Recruiting·EEgymedicalpedia·N/A·NCT06370078·46 enrolled

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06533748·128 enrolled

Prophylactic Minimally Invasive Surfactant Evaluation

Recruiting·EEndeavor Health·Phase 4·NCT06007547·200 enrolled

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

Recruiting·—·Phase 1·NCT07078929·16 enrolled

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 1·NCT06709469·10 enrolled

Page 1 of 44

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)